Biocon Biologics gets credit boost from S&P, outlook stable
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Subscribe To Our Newsletter & Stay Updated